Beta thalassemia

Beta thalassemia
National Heart Lung and Blood Institute (NIH) · Public domain · source
Name	Beta thalassemia
Field	Hematology
Symptoms	Anemia, fatigue, jaundice, hepatosplenomegaly
Complications	Iron overload, cardiac disease, endocrine dysfunction
Onset	Variable; infancy to adulthood
Causes	Mutations in HBB gene
Diagnosis	Hemoglobin electrophoresis, genetic testing
Treatment	Transfusions, chelation, hematopoietic stem cell transplantation

Beta thalassemia is an inherited hemoglobinopathy characterized by reduced or absent synthesis of the beta chains of hemoglobin, leading to ineffective erythropoiesis and variable anemia. It presents across a spectrum ranging from asymptomatic carrier states to severe transfusion-dependent disease, and it has shaped public health policy in regions such as the Mediterranean, Middle East, and Southeast Asia.

Signs and symptoms

Patients may present with pallor, fatigue, and dyspnea on exertion alongside physical findings such as frontal bossing and hepatosplenomegaly, which mirror clinical descriptions from cases seen in institutions like Great Ormond Street Hospital and Mayo Clinic. Severe forms often show failure to thrive in infancy and transfusion dependence similar to early reports from Royal Free Hospital and case series published by researchers at Harvard Medical School and Johns Hopkins Hospital. Chronic hemolysis and ineffective erythropoiesis produce jaundice and gallstones, complications cataloged in cohorts from Cairo University and University of Athens. Long-term sequelae include secondary iron overload with cardiac failure, endocrinopathies such as hypogonadism, and growth retardation documented in studies at University of Oxford and Karolinska Institutet.

Genetics and pathophysiology

The molecular basis involves mutations of the HBB gene on chromosome 11, first mapped in linkage studies involving groups such as researchers at Cold Spring Harbor Laboratory and National Institutes of Health. Mutations include point mutations, small deletions, and splice-site changes described by laboratories at University of Cambridge and Stanford University School of Medicine. These defects reduce beta-globin synthesis, shifting globin chain balance and producing excess alpha chains that precipitate in erythroid precursors, a mechanism elucidated in experiments from Imperial College London and University of California, San Francisco. The resulting ineffective erythropoiesis drives marrow expansion, extramedullary hematopoiesis observed historically in patients from Mount Sinai Hospital cohorts, and heightened intestinal iron absorption mediated in part by hepcidin pathways studied at University of Barcelona and University College London.

Diagnosis

Diagnosis integrates hematologic indices, hemoglobin electrophoresis, high-performance liquid chromatography used in laboratories at Mayo Clinic, and molecular genetic testing performed by centers such as Broad Institute and Wellcome Sanger Institute. Peripheral blood films and reticulocyte counts, tools used at Karolinska Universitetssjukhuset, reveal microcytosis and anisopoikilocytosis; electrophoretic patterns distinguish beta-thalassemia trait from iron deficiency as noted in protocols from University of Toronto and Johns Hopkins University. Prenatal diagnostic approaches pioneered at Karolinska Institutet and University of Edinburgh include chorionic villus sampling and cell-free fetal DNA testing, and carrier screening programs modeled on initiatives by World Health Organization members guide population-level detection.

Classification and types

Clinical categories reflect severity: carriers or beta-thalassemia minor, intermedia, and major, classifications discussed in consensus statements by committees at European Hematology Association and American Society of Hematology. Molecular classification distinguishes beta0 (no beta-globin production) and beta+ (reduced production) alleles, terms applied in genotype-phenotype correlation studies from University of Athens and National and Kapodistrian University of Athens. Compound heterozygosity with abnormal hemoglobins such as HbS or HbE, first characterized in reports from University of Lagos and University of Colombo, further modifies clinical course.

Management and treatment

Supportive and disease-modifying strategies include regular red blood cell transfusion regimens laid out by guidelines from NICE and American Association of Blood Banks, iron chelation therapy with agents developed by pharmaceutical collaborations involving Novartis and Bayer, and hematopoietic stem cell transplantation performed at transplant centers like St Jude Children's Research Hospital and Fred Hutchinson Cancer Center. Emerging therapies include gene addition and gene editing trials led by groups at University of California, Berkeley, CRISPR Therapeutics, and Bluebird Bio, and pharmacologic HbF induction with agents such as hydroxyurea informed by clinical trials from National Cancer Institute and European Medicines Agency. Multidisciplinary care models involving endocrinology clinics at Mayo Clinic and cardiology units at Cleveland Clinic address complications of iron overload.

Epidemiology

Beta thalassemia is most prevalent in populations from the Mediterranean basin, Middle East, Indian subcontinent, and Southeast Asia, with prevalence described in national registries from Greece, Cyprus, Italy, Iran, India, and Thailand. Migration has altered distribution patterns noted in demographic studies from United Kingdom and United States public health agencies, prompting screening policies modeled on programs from Cyprus National Thalassemia Prevention Program and initiatives by World Health Organization regional offices. Carrier frequencies vary widely, and population genetics research from University of Bologna and Pasteur Institute has explored selective pressures including historical malaria endemicity as a contributing factor.

History and research advancements

Clinical recognition dates to 19th-century observations in patients seen at hospitals like Guy's Hospital and early pathologic descriptions emerging from work at King's College London. The term and genetic understanding advanced through 20th-century discoveries at University of Illinois at Chicago and University of Geneva, with molecular characterization of HBB mutations achieved in laboratories such as Sanger Institute and University of California, San Diego. Major research milestones include development of iron chelators by collaborations involving Novartis and transplantation protocols refined at Great Ormond Street Hospital. Contemporary breakthroughs in gene therapy and genome editing reported by teams at Boston Children's Hospital, St Jude Children's Research Hospital, and CRISPR Therapeutics have progressed from preclinical models at Massachusetts Institute of Technology to multicenter clinical trials, reshaping prospects for curative treatment.

Category:Hemoglobinopathies